Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: A prospective study

Lung Cancer

Volumn 61, Issue 3, 2008, Pages 378-384

  Berghmans, Thierry ^a   Gourcerol, Delphine ^b   Lafitte, Jean Jacques ^b   Kotsori, Katerina ^c   Paesmans, Marianne ^a   Scherpereel, Arnaud ^b   Leclercq, Nathalie ^a   Sculier, Jean Paul ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Cisplatin; Mitomycin; Non small cell lung cancer; Salvage chemotherapy; Taxane; Vinorelbine

Indexed keywords

CISPLATIN; MITOMYCIN; NAVELBINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY DISTRESS; SEPTIC SHOCK; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT DISEASE; VOMITING;

EID: 50849142209     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.01.011     Document Type: Article

References (26)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Berghmans T., Paesmans M., Meert A.P., Mascaux C., Lothaire P., Lafitte J.J., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 (2005) 13-23
3. Donnadieu N., Paesmans M., and Sculier J.P. Chimiothérapie du cancer bronchique non à petites cellules. Méta-analyse de la littérature en fonction de l'extention de la maladie. Rev Mal Respir 8 (1991) 197-204
4. Meert A.P., Berghmans T., Branle F., Lemaitre F., Mascaux C., Rubesova E., et al. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res 19 (1999) 4379-4390
5. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21 (2003) 2237-2246
6. Shepherd F.A., Rodrigues P.J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
7. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
8. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
9. Fossella F., Pereira J.R., von P.J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 3016-3024
10. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
11. Sculier J.P., Ghisdal L., Berghmans T., Branle F., Lafitte J.J., Vallot F., et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer 84 (2001) 1150-1155
12. Gridelli C., Airoma G., Incoronato P., Pepe R., Palazzolo G., Rossi A., et al. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 30 (1992) 212-214
13. Kris M.G., Gralla R.J., Kelsen D.P., Casper E.S., Burke M.T., Fiore J.J., et al. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest 87 (1985) 368-372
14. Sculier J.P., Klastersky J., Dumont J.P., Vandermoten G., Rocmans P., Libert P., et al. Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium). Cancer Treat Rep 70 (1986) 773-775
15. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., Blum R.H., Green M.D., Mason B., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7 (1989) 1602-1613
16. Jacoulet P., Dubiez A., Westeel V., Polio J.C., Pernet D., and Depierre A. Chimiothérapie de deuxième ligne chez les patients réfractaires et résistants atteints de cancers du poumon non à petites cellules. Rev Mal Respir 14 (1997) 29-35
17. Camps C., Martinez E.N., and Jaime A.B. Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 27 (2000) 47-53
18. Hainsworth J.D., Burris III H.A., Litchy S., Erland J.B., Hon J.K., Brierre J.E., et al. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial. Cancer 88 (2000) 1353-1358
19. Babiak A., Hetzel J., Godde F., Konig H.H., Pietsch M., and Hetzel M. Mitomycin C and vinorelbine for second-line chemotherapy in NSCLC-a phase II trial. Br J Cancer 96 (2007) 1052-1056
20. European Lung Cancer Working Party (E.L.C.W.P.). European Lung Cancer Working Party clinical practice guidelines: clinical practice guidelines. Non-small cell lung cancer. III. Metastatic disease. Hosp Chron 1 3 (2006) 169-185
21. Barlesi F., Jacot W., Astoul P., and Pujol J.L. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer 51 (2006) 159-172
22. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De M.F., von P.J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
23. Thatcher N., Chang A., Parikh P., Rodrigues P.J., Ciuleanu T., von P.J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
24. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
25. Wibmer T., Kropf C., Merk T., Schumann C., Hombach V., and Kruger S. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer. Lung Cancer (2007)
26. Berghmans T., Lafitte J.J., Lecomte J., Alexopoulos C.G., Van C.O., Giner V., et al. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer 96 (2007) 1644-1649